Back Back
Cell No. : Cell Name
HPS1046 :  update : 2024/02/28
CommentDisease specific iPS cell line derived from a healthy person.
Comment from the depositor
Terms and conditions1) In relation to the for-profit organizations, please contact iPS Academia Japan, Inc., prior to the utilization of iPS cells. 2) Attach Appendix (non-for-profit) or Appendix (for-profit) to MTA (C-0007 or C-0007p) . 3) The RECIPIENT agrees to obtain the prior written approval of the distribution from the APPROVER. 4) Contact Us : RIKEN Cell Bank
Order Form Order Form(C-0042.pdf)   Approval Form(C-0057.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Year of deposit 2015
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 40s
Tissue blood mononuclear cell
Classification iPS
Recombinant recombinant
Exogene Oct3/4, Sox2, Klf4, L-Myc, Lin28, mp53DD, EBNA1
Lifespan infinite
Morphology ES-like
Cellosaurus(Expasy) CVCL_UN19
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium StemFit AK02N
Antibiotics Free
Passage method TrypLE Select CTS : 0.5 mM EDTA/PBS(-) = 1 : 1
Coating dish 0.5 μg/cm 2 Laminin-511 E8 (iMatrix511)
Culture information Passage cell No 2.6-26x10 4 cells/60 mm dish
SC frequency Subculture : once/5-10 days, Medium Renewal : every day or every other day
Temperature 37 ℃
CO2 concentration 5 %
Feeder cells Free
Freeze medium StemFit AK02N + 10 μM Y-27632 + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) Undetected
Virus (HTLV-1) (-)
Chromosome mode 46,XY [20]
Others Use 10μM Y-27632 when passaging and thawing. Remove it next day.
STR(human) OK
deposit info
lot info
Reference information Reference 2
User's Publication 2

To topTop
4005  Kondo T, Imamura K, Funayama M, Tsukita K, Miyake M, Ohta A, Woltjen K, Nakagawa M, Asada T, Arai T, Kawakatsu S, Izumi Y, Kaji R, Iwata N, Inoue H.  iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease.  Cell Rep  2017  21:2304-2312  PubMed ID: 29166618   DOI: 10.1016/j.celrep.2017.10.109
4543  Matsuzono K, Imamura K, Murakami N, Tsukita K, Yamamoto T, Izumi Y4, Kaji R, Ohta Y, Yamashita T, Abe K, Inoue H.  Antisense Oligonucleotides Reduce RNA Foci in Spinocerebellar Ataxia 36 Patient iPSCs.  Mol Ther Nucleic Acids  2017  15;8:211-219  PubMed ID: 28918022   DOI: 10.1016/j.omtn.2017.06.017

To topTop
User's Publication
19551  Nonaka H, Kondo T, Suga M, Yamanaka R, Sagara Y, Tsukita K, Mitsutomi N, Homma K, Saito R, Miyoshi F, Ohzeki H, Okuyama M, Inoue H.  Induced pluripotent stem cell-based assays recapture multiple properties of human astrocytes  J Cell Mol Med  2024  28(7):e18214  PubMed ID: 38509731   DOI: 10.1111/jcmm.18214
11410  Sekine SI, Nishii K, Masaka T, Kurita H, Inden M, Hozumi I.  SLC20A2 variants cause dysfunctional phosphate transport activity in endothelial cells induced from Idiopathic Basal Ganglia Calcification patients-derived iPSCs.  Biochem. Biophys. Res. Commun.  2019    PubMed ID: 30704756   DOI: 10.1016/j.bbrc.2019.01.096

Back Back Return Top Page